Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update
Rigel Pharmaceuticals (Nasdaq: RIGL), a biotechnology company focused on hematologic disorders and cancer therapies, will report its second quarter 2025 financial results after market close on Tuesday, August 5, 2025.
The company will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss financial results and provide a business update. Investors can join via phone or access the webcast through Rigel's investor relations website, where it will remain available for replay for 90 days.
Rigel Pharmaceuticals (Nasdaq: RIGL), un'azienda biotecnologica specializzata in disturbi ematologici e terapie oncologiche, comunicher脿 i suoi risultati finanziari del secondo trimestre 2025 dopo la chiusura del mercato, marted矛 5 agosto 2025.
L'azienda terr脿 una conference call e una diretta web alle 16:30 ora della costa orientale per discutere i risultati finanziari e fornire un aggiornamento sull'attivit脿. Gli investitori potranno partecipare telefonicamente o seguire la diretta sul sito web delle relazioni con gli investitori di Rigel, dove sar脿 disponibile per la visione in differita per 90 giorni.
Rigel Pharmaceuticals (Nasdaq: RIGL), una compa帽铆a biotecnol贸gica centrada en trastornos hematol贸gicos y terapias contra el c谩ncer, presentar谩 sus resultados financieros del segundo trimestre de 2025 despu茅s del cierre del mercado el martes 5 de agosto de 2025.
La empresa realizar谩 una llamada conferencia y una transmisi贸n en vivo a las 4:30 p.m., hora del Este para discutir los resultados financieros y ofrecer una actualizaci贸n del negocio. Los inversores podr谩n unirse por tel茅fono o acceder a la transmisi贸n a trav茅s del sitio web de relaciones con inversores de Rigel, donde estar谩 disponible para reproducci贸n durante 90 d铆as.
Rigel Pharmaceuticals (雮橃姢雼�: RIGL)電� 順堨暋 歆堩櫂 氚� 鞎� 旃橂鞐� 欷戩爯鞚� 霊� 靸濍獏瓿淀暀 須岇偓搿�, 2025雲� 2攵勱赴 鞛 瓴瓣臣毳� 2025雲� 8鞗� 5鞚� 頇旍殧鞚� 鞁滌灔 毵堦皭 頉勳棎 氚滍憸頃� 鞓堨爼鞛呺媹雼�.
须岇偓电� 霃欕秬 響滌鞁� 鞓ろ泟 4鞁� 30攵�鞐� 鞛 瓴瓣臣毳� 雲检潣頃橁碃 靷梾 順勴櫓鞚� 鞐呺嵃鞚错姼頃橁赴 鞙勴暅 旎嵓霟办姢 旖滉臣 鞗轨簮鞀ろ姼毳� 歆勴枆頃╇媹雼�. 韴瀽鞛愲姅 鞝勴檾搿� 彀胳棳頃橁卑雮� Rigel 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 鞗轨簮鞀ろ姼鞐� 鞝戩啀頃� 靾� 鞛堨溂氅�, 頃措嫻 鞗轨簮鞀ろ姼電� 90鞚� 霃欖晥 雼れ嫓氤搓赴搿� 鞝滉车霅╇媹雼�.
Rigel Pharmaceuticals (Nasdaq : RIGL), une entreprise biotechnologique sp茅cialis茅e dans les troubles h茅matologiques et les th茅rapies contre le cancer, publiera ses r茅sultats financiers du deuxi猫me trimestre 2025 apr猫s la cl么ture du march茅 le mardi 5 ao没t 2025.
L'entreprise organisera une conf茅rence t茅l茅phonique et une diffusion en direct 脿 16h30, heure de l'Est pour discuter des r茅sultats financiers et fournir une mise 脿 jour commerciale. Les investisseurs pourront participer par t茅l茅phone ou acc茅der au webcast via le site des relations investisseurs de Rigel, o霉 il restera disponible en replay pendant 90 jours.
Rigel Pharmaceuticals (Nasdaq: RIGL), ein Biotechnologieunternehmen mit Fokus auf h盲matologische Erkrankungen und Krebstherapien, wird seine Finanzergebnisse f眉r das zweite Quartal 2025 nach B枚rsenschluss am Dienstag, den 5. August 2025 bekanntgeben.
Das Unternehmen wird um 16:30 Uhr Eastern Time eine Telefonkonferenz und Webcast abhalten, um die Finanzergebnisse zu besprechen und ein Unternehmensupdate zu geben. Investoren k枚nnen telefonisch teilnehmen oder den Webcast 眉ber die Investor-Relations-Website von Rigel verfolgen, wo er f眉r 90 Tage als Aufzeichnung verf眉gbar bleibt.
- None.
- None.
Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international).听The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's website at .听The webcast will be archived and available for replay for 90 days after the call via the Rigel website.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in
Contact for Investors & Media: 听
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
[email protected]听
Media:
David Rosen
Argot Partners
Phone: 646.461.6387
贰尘补颈濒:鈥�[email protected]听
听
View original content to download multimedia:
SOURCE Rigel Pharmaceuticals, Inc.
FAQ
When will Rigel Pharmaceuticals (RIGL) report Q2 2025 earnings?
How can investors access Rigel's Q2 2025 earnings call?
What time is Rigel's Q2 2025 earnings call?
How long will Rigel's Q2 2025 earnings webcast be available for replay?
What is Rigel Pharmaceuticals' main business focus?
